The specialist cancer drug discovery and development business has announced that the Clinical Trial Applications for Phase I clinical trials of CCT245737, the CHK1 Programme clinical development candidate drug, were submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 29 January 2016. This is on schedule and we understand that the MHRA typically takes up to thirty days to process applications subject to there being no further requests for information. With this in
03 Feb 2016
CHK1 Phase 1 CTA submitted on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CHK1 Phase 1 CTA submitted on track
Sareum Holdings plc (SAR:LON) | 29.5 1.8 26.9% | Mkt Cap: 30.0m
- Published:
03 Feb 2016 -
Author:
Derren Nathan -
Pages:
6
The specialist cancer drug discovery and development business has announced that the Clinical Trial Applications for Phase I clinical trials of CCT245737, the CHK1 Programme clinical development candidate drug, were submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 29 January 2016. This is on schedule and we understand that the MHRA typically takes up to thirty days to process applications subject to there being no further requests for information. With this in